Circulating cell-free RNA in blood as a host response biomarker for detection of tuberculosis

被引:1
|
作者
Chang, Adrienne [1 ]
Loy, Conor J. [1 ]
Eweis-LaBolle, Daniel [1 ]
Lenz, Joan S. [1 ]
Steadman, Amy [2 ]
Andgrama, Alfred [3 ]
Nhung, Nguyen Viet [4 ]
Yu, Charles [5 ]
Worodria, William [3 ]
Denkinger, Claudia M. [6 ,7 ]
Nahid, Payam [8 ]
Cattamanchi, Adithya [8 ,9 ]
De Vlaminck, Iwijn [1 ]
机构
[1] Cornell Univ, Meinig Sch Biomed Engn, Ithaca, NY 14850 USA
[2] Global Hlth Labs Inc, Bellevue, WA USA
[3] World Alliance Lung & Intens Care Med Uganda, Kampala, Uganda
[4] Natl Lung Hosp, Hanoi, Vietnam
[5] De La Salle Med & Hlth Sci Inst, Dasmarinas, Philippines
[6] Univ Hosp Heidelberg, Heidelberg, Germany
[7] German Ctr Infect Res, Heidelberg, Germany
[8] Univ Calif San Francisco, UCSF Ctr TB, San Francisco, CA USA
[9] Univ Calif Irvine, Div Pulm & Crit Care Med, Orange, CA USA
基金
美国国家卫生研究院;
关键词
PULMONARY TUBERCULOSIS; SIGNATURE; EXPRESSION;
D O I
10.1038/s41467-024-49245-6
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tuberculosis (TB) remains a leading cause of death from an infectious disease worldwide, partly due to a lack of effective strategies to screen and triage individuals with potential TB. Whole blood RNA signatures have been tested as biomarkers for TB, but have failed to meet the World Health Organization's (WHO) optimal target product profiles (TPP). Here, we use RNA sequencing and machine-learning to investigate the utility of plasma cell-free RNA (cfRNA) as a host-response biomarker for TB in cohorts from Uganda, Vietnam and Philippines. We report a 6-gene cfRNA signature, which differentiates TB-positive and TB-negative individuals with AUC = 0.95, 0.92, and 0.95 in test, training and validation, respectively. This signature meets WHO TPPs (sensitivity: 97.1% [95% CI: 80.9-100%], specificity: 85.2% [95% CI: 72.4-100%]) regardless of geographic location, sample collection method and HIV status. Overall, our results identify plasma cfRNA as a promising host response biomarker to diagnose TB. Whole blood signatures have served as the potential biomarkers for TB but failed to meet World Health Organization's (WHO) optimal target product profiles (TPP). By employing cohorts from multiple countries, the authors identify a diagnostic 6-gene signature from cell free RNA which outperforms TPP requirement in distinguishing TB from non-TB.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities
    Zaporozhchenko, Ivan A.
    Ponomaryova, Anastasia A.
    Rykova, Elena Yu
    Laktionov, Pavel P.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2018, 18 (02) : 133 - 145
  • [2] Plasma circulating cell-free messenger RNA as a potential biomarker of melanoma
    Ita, M. I.
    Wang, J. H.
    Fanning, N.
    Kaar, G. F.
    Lim, C. H.
    Redmond, H. P.
    BRITISH JOURNAL OF SURGERY, 2021, 108
  • [3] Plasma Circulating Cell-Free Messenger RNA as a Potential Biomarker of Melanoma
    Ita, M.
    Wang, J. H.
    Fanning, N.
    Kaar, G.
    Lim, C.
    Redmond, H.
    BRITISH JOURNAL OF SURGERY, 2021, 108
  • [4] Circulating cell-free mtDNA as a new biomarker for cancer detection and management
    Peng, Fan
    Wang, Siyuan
    Feng, Zehui
    Zhou, Kaixiang
    Zhang, Huanqin
    Guo, Xu
    Xing, Jinliang
    Liu, Yang
    CANCER BIOLOGY & MEDICINE, 2024, 21 (02) : 105 - 110
  • [5] Circulating cell-free mtDNA as a new biomarker for cancer detection and management
    Fan Peng
    Siyuan Wang
    Zehui Feng
    Kaixiang Zhou
    Huanqin Zhang
    Xu Guo
    Jinliang Xing
    Yang Liu
    Cancer Biology & Medicine, 2024, 21 (02) : 105 - 110
  • [6] Circulating tumor derived cell-free RNA (cfRNA) as a potential biomarker in melanoma
    Albrecht, L. J.
    Varaljai, R.
    Hoewner, A.
    Lueong, S. S.
    von Neuhof, N.
    Sucker, A.
    Sondermann, W.
    Schadendorf, D.
    Roesch, A.
    EXPERIMENTAL DERMATOLOGY, 2022, 31 (02) : E26 - E27
  • [7] Circulating cell-free DNA content as blood based biomarker in endometrial cancer
    Cicchillitti, Lucia
    Corrado, Giacomo
    De Angeli, Martina
    Mancini, Emanuela
    Baiocco, Ermelinda
    Patrizi, Lodovico
    Zampa, Ashanti
    Merola, Roberta
    Martayan, Aline
    Conti, Laura
    Piaggio, Giulia
    Vizza, Enrico
    ONCOTARGET, 2017, 8 (70) : 115230 - 115243
  • [8] Circulating cell-free DNA - A novel biomarker for response to therapy in ovarian carcinoma
    Kamat, Aparna A.
    Bischoff, Farideh Z.
    Dang, Dianne
    Baldwin, Matthew F.
    Han, Liz Y.
    Lin, Yvonne G.
    Merritt, William M.
    Landen, Charles N.
    Lu, Chunhua
    Gershenson, David M.
    Simpson, Joe L.
    Sood, Anil K.
    CANCER BIOLOGY & THERAPY, 2006, 5 (10) : 1369 - 1374
  • [9] The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study
    Ita, M. I.
    Wang, J. H.
    Toulouse, A.
    Lim, C. H.
    Fanning, N.
    O'Sullivan, M. G. J.
    Nolan, Y.
    Kaar, G. F.
    Redmond, H. P.
    BRITISH JOURNAL OF SURGERY, 2021, 108
  • [10] The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study
    Ita, Michael Itak
    Wang, Jiang Huai
    Toulouse, Andre
    Lim, Chris
    Fanning, Noel
    O'Sullivan, Michael
    Nolan, Yvonne
    Kaar, George Finbarr
    Redmond, Henry Paul
    ACTA NEUROCHIRURGICA, 2022, 164 (03) : 723 - 735